Literature DB >> 2997790

Identification and expression of a nuclear antigen from the genomic region of the Jijoye strain of Epstein-Barr virus that is missing in its nonimmortalizing deletion mutant, P3HR-1.

D Rowe, L Heston, J Metlay, G Miller.   

Abstract

An Epstein-Barr virus (EBV) deletion mutant, HR-1, cannot immortalize lymphocytes. HR-1 was derived from a virus strain, Jijoye, that is immortalization competent. Using human antiserum from certain patients with chronic active EBV infection, we have identified in Jijoye cells a protein of apparent mass of 78-80 kDa that is missing in cells with the HR-1 genome. A protein of identical size and antigenicity has been stably expressed in mouse LTK- cells by gene transfer with cloned Jijoye EBV DNA that encompasses the deletion in the HR-1 genome. The expressed product is a nuclear neoantigen. The polypeptide we have identified is likely to be essential in the immortalization process.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997790      PMCID: PMC391358          DOI: 10.1073/pnas.82.21.7429

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction.

Authors:  J Menezes; W Leibold; G Klein
Journal:  Exp Cell Res       Date:  1975-05       Impact factor: 3.905

2.  Transformation by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H.

Authors:  J Skare; J Farley; J L Strominger; K O Fresen; M S Cho; H zur Hausen
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

Review 3.  The oncogenicity of Epstein-Barr virus.

Authors:  G Miller
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

4.  Identification of the filtrable leukocyte-transforming factor of QIMR-WIL cells as herpes-like virus.

Authors:  J H Pope; M K Horne; W Scott
Journal:  Int J Cancer       Date:  1969-05-15       Impact factor: 7.396

5.  Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis.

Authors:  T B Sculley; P J Walker; D J Moss; J H Pope
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

6.  Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells.

Authors:  J L Yates; N Warren; B Sugden
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

7.  A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes.

Authors:  H K Adldinger; H Delius; U K Freese; J Clarke; G W Bornkamm
Journal:  Virology       Date:  1985-03       Impact factor: 3.616

8.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

9.  Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells.

Authors:  W Henle; V Diehl; G Kohn; H Zur Hausen; G Henle
Journal:  Science       Date:  1967-09-01       Impact factor: 47.728

10.  U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2.

Authors:  T Dambaugh; K Hennessy; L Chamnankit; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

View more
  20 in total

1.  BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins.

Authors:  A Ricksten; B Kallin; H Alexander; J Dillner; R Fåhraeus; G Klein; R Lerner; L Rymo
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells.

Authors:  T Dambaugh; F Wang; K Hennessy; E Woodland; A Rickinson; E Kieff
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences.

Authors:  J M Burrows; R Khanna; T B Sculley; M P Alpers; D J Moss; S R Burrows
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells.

Authors:  A B Rickinson; L S Young; M Rowe
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

5.  Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.

Authors:  C Rooney; N Taylor; J Countryman; H Jenson; J Kolman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  Deletion mutants that affect expression of Epstein-Barr virus nuclear antigen in COS-1 cells after gene transfer with simian virus 40 vectors containing portions of the BamHI K fragment.

Authors:  M Polvino-Bodnar; D Shedd; G Miller
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

7.  The analysis of EBV proteins which are antigenic in vivo.

Authors:  D Walls; M Perricaudet; F Gannon
Journal:  Nucleic Acids Res       Date:  1988-04-11       Impact factor: 16.971

8.  Isolation and characterization of cDNA clones corresponding to transcripts from the BamHI H and F regions of the Epstein-Barr virus genome.

Authors:  A J Pfitzner; E C Tsai; J L Strominger; S H Speck
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

9.  Mapping of the gene coding for Epstein-Barr virus-determined nuclear antigen EBNA3 and its transient overexpression in a human cell line by using an adenovirus expression vector.

Authors:  I Joab; D T Rowe; M Bodescot; J C Nicolas; P J Farrell; M Perricaudet
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

10.  The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.

Authors:  Sinéad Keating; Stuart Prince; Matthew Jones; Martin Rowe
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.